By Karen Roman
Pharmaceutical company Aspargo Laboratories released a Phase 1 study showing its oral spray for erectile dysfunction achieves absorption within five minutes, twice as fast as existing sildenafil tablets.
ASP-001 uses sildenafil, the active ingredient in Viagra (Nasdaq: VTRS) with regulatory approval in the US, Mexico and the UK, among other countries, it said.
“Our innovative oral spray technology has been carefully developed to provide a novel approach for administering medication, simplifying the process of drug consumption,” said Michael Demurjian, Aspargo Labs’ CEO.
The company seeks to obtain a new drug application from the Food and Drug Administration to make ASP-001 the first approved oral spray for ED, it said in a statement. Aspargo will also pursue oral suspensions and solutions for other prescriptions which are now only available as tablets, it said.
Contact:
Editor@executives-edge.com
